Welcome to our dedicated page for Dogwood Therapeutics news (Ticker: DWTX), a resource for investors and traders seeking the latest updates and insights on Dogwood Therapeutics stock.
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) is a development-stage biopharmaceutical company whose news flow centers on the clinical and corporate progress of its pain and neuropathy programs. The company regularly issues updates on Halneuron®, its lead non-opioid NaV 1.7 analgesic in Phase 2b development for chemotherapy-induced neuropathic pain (CINP), as well as on SP16 IV, its LRP1 agonist candidate with potential to treat neuropathy and repair nerve damage following chemotherapy.
News items for DWTX commonly include interim clinical trial readouts, enrollment milestones and study design details for the HALT-CINP Phase 2b trial, where Dogwood reports on safety, tolerability and pain improvement data compared with placebo. The company also provides announcements on regulatory designations, such as FDA fast track status for Halneuron® in CINP, and on preclinical findings that describe mechanisms like NaV 1.7 modulation and LRP1-mediated anti-inflammatory and neural repair activity.
Investors following Dogwood’s news can expect coverage of financing transactions, including registered direct offerings, concurrent private placements and equity incentive plan approvals disclosed through press releases and Form 8-K filings. The company’s communications also highlight licensing deals, such as the exclusive, royalty-free global license for SP16 IV, and describe how these transactions expand the research pipeline in cancer-related pain and chemotherapy-induced neuropathy.
Additional news categories include participation in investor conferences and scientific meetings, where Dogwood’s management discusses the Halneuron® pain research program, synthetic manufacturing advances and the antiviral platform involving IMC-1 and IMC-2 for fibromyalgia and Long-COVID. For readers interested in DWTX, this news page aggregates these clinical, regulatory, financial and partnership developments in one place for ongoing reference.
Dogwood Therapeutics (NASDAQ:DWTX) has reported its Q2 2025 financial results, highlighting progress in its Halneuron® Phase 2b trial for Chemotherapy-Induced Neuropathic Pain (CINP). The company has enrolled 52 patients with a low discontinuation rate of 5.8%, suggesting good tolerability. The interim data readout remains on track for Q4 2025.
The company's pipeline includes Halneuron®, which has received FDA fast track designation for CINP treatment, and IMC-1 for Fibromyalgia. Financial results show R&D expenses of $2.5 million and a net loss of $3.8 million. With $13.4 million cash on hand, Dogwood has operational runway through Q1 2026.
Dogwood Therapeutics (NASDAQ:DWTX) has reached a significant milestone in its Phase 2b clinical trial for Halneuron®, enrolling the first 50 patients to evaluate the drug's effectiveness in treating Chemotherapy-Induced Neuropathic Pain (CINP). The trial, known as HALT-CINP, demonstrates promising early safety data with only a 6% discontinuation rate among the first 35 patients.
The study focuses on cancer patients with neuropathy from platinum or taxane-based chemotherapy, administering 8 daily subcutaneous doses over 14 days with a 28-day follow-up. The company remains on track for its Q4 2025 interim analysis of approximately 100 patients, with full results expected in mid-2026. The trial will be conducted across 25 U.S. sites, evaluating primary endpoints of safety and pain intensity reduction.
Dogwood Therapeutics (Nasdaq: DWTX), a development-stage biotech company focused on developing treatments for pain and fatigue-related disorders, will release its Q2 2025 financial results on Wednesday, August 13, 2025, before market open.
Dogwood Therapeutics (NASDAQ: DWTX) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. CEO and Chairman Greg Duncan will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Those interested in scheduling meetings can contact John Perez at jperez@dboralcapital.com for registration.
Dogwood Therapeutics (DWTX) has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, following a notification of non-compliance received on November 15, 2024. The company submitted a compliance plan on December 27, 2024, and was granted until May 14, 2025, to meet the requirement.
The biopharmaceutical company, focused on developing medicines for pain and fatigue-related disorders, reports a strong cash position of $17.5 million as of Q1. DWTX is currently conducting a Phase 2b trial for Halneuron® in Chemotherapy Induced Neuropathic Pain, with interim data analysis planned for Q4 2025.
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) announced it believes it has regained compliance with Nasdaq's minimum stockholders’ equity requirement, as per Listing Rule 5550(b)(1). The company, focused on developing medicines for pain and fatigue-related disorders, has a strong cash position of $17.5 million with no debt as of Q1 end. On November 15, 2024, DWTX was notified it fell below the $2.5 million minimum equity requirement. A compliance plan was submitted on December 27, 2024, and Nasdaq granted an extension until May 14, 2025. Key transactions include a Debt Exchange and Cancellation Agreement with Conjoint, Inc., converting $19.9 million in debt to Series A-1 Non-Voting Convertible Preferred Stock, and a stock purchase agreement raising $4.8 million from institutional investors. As of March 31, 2025, DWTX had 1,911,128 shares of common stock outstanding.
Dogwood Therapeutics (NASDAQ: DWTX) has reported its Q4 and full-year 2024 financial results, highlighting significant developments in its pipeline. The company has begun dosing patients in the Halneuron® Phase 2b trial for Chemotherapy Induced Neuropathic Pain (CINP), with interim data expected in Q4 2025.
Financial highlights include a $19.5M debt-to-equity conversion by major shareholder CK Life Sciences, and a $4.8M common stock raise, extending operational runway through Q1 2026. The company reported a Q4 2024 net loss of $8.2M ($6.29 per share) compared to $1.1M in Q4 2023. Full-year 2024 net loss was $12.9M ($12.52 per share).
R&D expenses increased to $2.3M in Q4 2024 from $0.3M in Q4 2023, while G&A expenses rose to $5.2M from $0.8M. Cash position stands at $14.8M as of December 31, 2024.
Dogwood Therapeutics (NASDAQ: DWTX) has initiated dosing in its Phase 2b clinical trial (HALT-CINP) evaluating Halneuron® for chemotherapy-induced neuropathic pain (CINP). The drug targets the NaV 1.7 sodium channel and represents a potential opioid-free, addiction-free treatment for the $1.5B worldwide CINP market.
Halneuron® has demonstrated promising results in previous trials, showing statistically significant reduction in cancer-related pain with an acceptable safety profile. The drug has been tested in over 700 patients across Phase 1 and 2 studies, showing no addiction potential.
The company aims to recruit 100 CINP patients by Q4 2025, with an interim analysis planned for the same quarter. The adaptive trial design allows for potential study modifications to optimize outcomes.
FAQ
What is the current stock price of Dogwood Therapeutics (DWTX)?
What is the market cap of Dogwood Therapeutics (DWTX)?
